Shares of Health Care sector company Incyte moved 4.0% today, and are now trading at a price of $56.9. The large-cap stock's daily volume was 1,543,275 compared to its average volume of 1,762,612. The S&P 500 index returned a 0.0% performance.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company is based in Wilmington and has 2,324 full time employees. Its market capitalization is $12,751,802,368.
18 analysts are following Incyte and have set target prices ranging from $58.0 to $93.0 per share. On average, they have given the company a rating of buy. At today's prices, INCY is trading -23.91% away from its average analyst target price of $74.78 per share.
Over the last year, INCY shares have gone down by -33.6%, which represents a difference of -49.0% when compared to the S&P 500. The stock's 52 week high is $86.29 per share and its 52 week low is $50.27. With average free cash flows of $433.09 Million that have been growing at an average rate of 10.1% over the last 6 years, Incyte declining stock performance may not be reflective of the quality of its underlying business.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 632,420 | 77,833 | 554,587 | -37.83 |
| 2022 | 969,941 | 77,833 | 892,108 | 56.93 |
| 2021 | 749,488 | 181,006 | 568,482 | 282.22 |
| 2020 | -124,599 | 187,379 | -311,978 | -149.32 |
| 2019 | 710,656 | 78,064 | 632,592 | 140.76 |
| 2018 | 336,227 | 73,483 | 262,744 |
